Literature DB >> 8721786

Cholesterol-lowering therapy may retard the progression of diabetic nephropathy.

H H Parving.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8721786     DOI： 10.1007/BF00418356

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  6 in total

1.  Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy.

Authors:  E Hommel; P Andersen; M A Gall; F Nielsen; B Jensen; P Rossing; J Dyerberg; H H Parving
Journal:  Diabetologia       Date:  1992-05       Impact factor: 10.122

2.  Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria.

Authors:  S Nielsen; O Schmitz; N Møller; N Pørksen; I C Klausen; K G Alberti; C E Mogensen
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

3.  Heterogeneous nature of renal lesions in type II diabetes.

Authors:  V Gambara; G Mecca; G Remuzzi; T Bertani
Journal:  J Am Soc Nephrol       Date:  1993-02       Impact factor: 10.121

4.  Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients.

Authors:  H H Parving; M A Gall; P Skøtt; H E Jørgensen; H Løkkegaard; F Jørgensen; B Nielsen; S Larsen
Journal:  Kidney Int       Date:  1992-04       Impact factor: 10.612

5.  Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria.

Authors:  P C Chan; J D Robinson; W C Yeung; I K Cheng; H W Yeung; M T Tsang
Journal:  Nephrol Dial Transplant       Date:  1992       Impact factor: 5.992

6.  Cholesterol-lowering therapy may retard the progression of diabetic nephropathy.

Authors:  K S Lam; I K Cheng; E D Janus; R W Pang
Journal:  Diabetologia       Date:  1995-05       Impact factor: 10.122
  6 in total
  2 in total

Review 1.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 2.  Lipids and diabetic renal disease.

Authors:  Mark E Cooper; Karin A M Jandeleit-Dahm
Journal:  Curr Diab Rep       Date:  2005-12       Impact factor: 4.810
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.